Turn this list into pipeline.
Biotech Companies in the UK: 2,400+ Active Firms (2026)
Biotech companies in the UK develop life-sciences technologies, treatments and biopharmaceutical processes within the MHRA-regulated market.
Buying centres tend to sit with R&D, clinical operations, manufacturing quality, regulatory affairs and corporate development, rather than a single software-style budget owner. The commercial motion is usually business-to-business: health R&D buyers, clinical-trial sponsors and biopharmaceutical value-chain partners assessing platforms, assets, services or regulated process capability. Smaller firms may be research-led suppliers or asset developers; mid-market and enterprise-facing operators are more likely to handle formal diligence, quality documentation and staged commercial agreements. Engagements tend to be high-consideration and evidence-led, with scientific validation, safety obligations and manufacturing readiness shaping buying decisions.
Read more
The UK cohort contains 2,474 actively trading biotech companies, making it a sizeable but still specialist slice of the wider life-sciences economy. The reported employment footprint is 1,719 people, concentrated among firms with disclosed headcount rather than necessarily the whole cohort. Commercial scale is relatively scarce: 112 firms have turnover above £5M. Company formation is still active, with 588 firms incorporated since 2022, which leaves a long tail of young operators alongside a smaller set of revenue-proven businesses.
Regulatory burden falls differently across the cohort because activities range from research platforms to clinical development, manufacturing and commercialisation. The MHRA sets standards, reviews clinical trial applications, assesses marketing authorisations and oversees post-authorisation pharmacovigilance. Trials also sit under Good Clinical Practice, ethics review and informed-consent requirements, while approved medicines can face health technology assessment by NICE before routine use in the public system. Sector representation is split by buyer and business model: the BioIndustry Association covers UK life-sciences and biotech companies, while the ABPI represents research-based pharmaceutical companies. For operators, evidence quality and safety monitoring are part of the sales process, not just compliance paperwork.
Future development appears likely to remain selective rather than broad-based. The cohort has an early-commercial tail, but buyers and partners tend to reward firms that can show reproducible science, credible safety evidence and a route through clinical, manufacturing or reimbursement scrutiny. Scale-up scarcity should keep partnerships, licensing and asset transactions central to market structure. Regulatory pressure may also favour operators with documented quality systems and experienced clinical teams. For younger firms, the harder task is not only proving scientific promise, but converting that promise into repeatable commercial demand without losing time to validation, funding cycles and approval pathways.
2,474
Active firms
2026
112
Above £5M
reported revenue
588
Since 2022
recent incorporations
Key facts
About 4% of the trading cohort reports turnover above £5M (112 of 2,474 firms) — the rest sits below that revenue band.
23% of the cohort was incorporated since 2022 (588 firms), so a sizeable share is in its first few filing cycles.
The MHRA approves clinical trial applications, assesses marketing authorisations and monitors post-authorisation safety through pharmacovigilance.
Clinical trials must follow Good Clinical Practice, ethics review and informed-consent requirements before human studies proceed.
Approved medicines may also be reviewed by NICE before routine NHS use, adding a market-access step after regulatory approval.
The UK life-sciences industry comprised 6,170 businesses across 7,320 companies in 2023/2024, generating £146.9 billion in turnover.
UK biotech raised £3.5 billion in equity investment in 2024, a 94% increase on 2023 and below £4.5 billion in 2021, with financing concentrated in a small number of large rounds.
Top UK biotech companies
Trajectory
5y · 2020–NowFinancial sub-scores
Computed from 5 filingsDevelops and manufactures biotechnology medicines including plasma‑derived and recombinant therapies, vaccines, and treatments for rare and serious diseases, iron deficiency and kidney conditions,…
Serves healthcare systems, public health bodies, clinicians and patients needing therapies for rare and serious diseases, iron deficiency, nephrology conditions and vaccines.
Financial Health
StrongStrong · 0% CAGR over 2y
Location
LFB BIOPHARMACEUTICALS LIMITED
Trajectory
5y · 2021–NowFinancial sub-scores
Computed from 5 filingsDevelops, manufactures and distributes biopharmaceutical medicines derived from human plasma, supplying therapies for immunology, haemostasis and intensive care. Involved in plasma collection,…
Serves healthcare providers, hospitals and health systems treating patients in immunology, haemostasis and intensive care, including users of plasma-derived therapies.
Financial Health
StrongStrong · Hiring · 22% CAGR over 4y
Location
Trajectory
5y · 2021–NowFinancial sub-scores
Computed from 5 filingsDevelops and commercialises biopharmaceutical medicines for rare diseases, with research and development focused on areas such as haematology and genetic disorders. Conducts clinical development,…
Serves healthcare professionals, hospitals and healthcare systems treating people with rare and debilitating diseases, including haematology, haemophilia and other rare-disease patient communities…
Financial Health
StrongStrong · Growing, Hiring · 16% CAGR over 4y
Location
AB BIOTECHNOLOGY LIMITED
Trajectory
4y · 2023–NowFinancial sub-scores
Computed from 4 filingsDevelops and manufactures biopharmaceutical products for research and clinical use. Provides services including peptide synthesis, protein purification, assay development, polyclonal antibody…
Serves biotechnology and pharmaceutical organisations developing biological medicinal or investigational medicinal products, including R&D, quality and manufacturing teams needing GMP-grade…
Financial Health
WeakWeak · -79% CAGR over 3y
Location
Lambda Therapeutic Limited
Trajectory
3y · 2023–NowFinancial sub-scores
Computed from 3 filingsProvides contract research services for pharmaceutical and biotechnology companies, including clinical trial management (Phase I–IV), regulatory affairs, biostatistics and data management,…
Serves biotech and pharmaceutical companies, including clinical development, regulatory, medical affairs and pharmacovigilance teams managing early-stage through Phase II-IV therapy programmes across…
Financial Health
HealthyHealthy · 0% CAGR over 2y
Location
ADVENT BIOSERVICES LIMITED
Trajectory
5y · 2021–NowFinancial sub-scores
Computed from 5 filingsProvides contract development and manufacturing services for cell and gene therapies. Operates GMP-compliant facilities for cell therapy production, process development, quality control testing, and…
Serves biotechnology and pharmaceutical companies developing cell and gene therapies, including organisations needing GMP production scale-up, process development, QC support and ultra-cold storage…
Financial Health
DistressedDistressed · -54% CAGR over 4y
Location
Develops and commercialises vaccines and diagnostic products, including tuberculosis skin tests, and supports vaccine manufacturing and supply initiatives. Engages in regulatory approvals, research…
Serves public health agencies, governments, healthcare systems and global health organisations procuring vaccines and diagnostics, as well as pharmaceutical partners in the UK, Europe, Africa and…
Location
Trajectory
3y · 2023–NowFinancial sub-scores
Computed from 3 filingsDevelops and supplies clinical diagnostic products and services, including laboratory analysers, reagents, quality control and external quality assessment schemes. Provides pathology testing,…
Serves clinical laboratories, healthcare providers, biopharma companies, employers needing workplace testing, food industry organisations, veterinary and forensic/toxicology labs, and consumers…
Financial Health
HealthyHealthy · 0% CAGR over 2y
Location
Trajectory
5y · 2021–NowFinancial sub-scores
Computed from 5 filingsDevelops and commercialises pharmaceutical therapies for rare diseases and critical care. Conducts preclinical research, clinical development and regulatory activities, and markets treatments in…
Serves healthcare providers, hospitals and patients in rare diseases and critical care, particularly cardiology, pulmonology, hemato-oncology and advanced therapies, with a European and global reach.
Financial Health
StableStable · -61% CAGR over 4y
Location
OXFORD BIOTHERAPEUTICS LTD
Trajectory
3y · 2023–NowFinancial sub-scores
Computed from 3 filingsResearches and develops antibody‑based cancer therapies, including antibody‑drug conjugates, T‑cell engagers and immuno‑oncology treatments. Uses proteomic platforms to identify cancer‑specific…
Serves pharmaceutical and biotechnology partners developing oncology treatments, including organisations working on ADCs, immuno-oncology, T-cell engagers and radiopharmaceuticals, with programmes…
Financial Health
HealthyHealthy
Location
Navitas Life Sciences Limited
Trajectory
5y · 2021–NowFinancial sub-scores
Computed from 5 filingsProvides contract research services to pharmaceutical, biotechnology and medical device organisations, including clinical trial management, bioavailability and bioequivalence studies, regulatory…
Serves global pharma, biotech and medical device sponsors, plus government agencies and non-profits involved in clinical development, regulatory, pharmacovigilance and post-market programmes.
Financial Health
HealthyHealthy · Hiring · 11% CAGR over 4y
Location
SEDA PHARMA DEVELOPMENT SERVICES LTD.
Trajectory
5y · 2021–NowFinancial sub-scores
Computed from 5 filingsProvides pharmaceutical development and clinical pharmacology services for pharmaceutical and biotechnology companies, including formulation development, laboratory testing, pharmacokinetic…
Serves B2B pharmaceutical and biotechnology companies developing drug candidates, from early-stage programmes through clinical development and marketing authorisation.
Financial Health
HealthyHealthy · -62% CAGR over 4y
Location
Trajectory
5y · 2020–NowFinancial sub-scores
Computed from 5 filingsProvides contract research services for pharmaceutical, biotechnology and consumer health companies, including clinical trial design and management, real‑world evidence and observational studies,…
Serves pharmaceutical, biotech and consumer health companies, including large pharma, developing drugs and medical devices across the UK, Ireland and Europe, with buyers in clinical research and…
Financial Health
StrongStrong
Location
Biovault Scientific Ltd
Trajectory
5y · 2021–NowFinancial sub-scores
Computed from 5 filingsProvides processing, storage and release of stem cells and human tissue products for cellular therapies and allografts. Operates biobanking facilities and offers cord blood and tissue storage,…
Serves NHS organisations, private clinics, and healthcare or life-science partners involved in cellular therapies, stem cells, human tissue, allografts, biobanking, and related clinical programmes.
Financial Health
StableStable · -5% CAGR over 4y
Location
Galvany Developments Ltd
Trajectory
5y · 2020–NowFinancial sub-scores
Computed from 5 filingsDevelops and commercialises niche pharmaceutical medicines across multiple therapeutic areas. Manages a portfolio of prescription drugs, including injectable treatments, and works with manufacturing…
Serves prescribers, retail pharmacies and hospital customers in the healthcare sector, with additional relationships with pharmaceutical manufacturers and commercial partners for co-development,…
Financial Health
HealthyHealthy
Location
BIO-DIAGNOSTICS LIMITED
Trajectory
5y · 2020–NowFinancial sub-scores
Computed from 5 filingsDevelops, manufactures and distributes medical diagnostic products including rapid antibody tests, allergy skin prick and patch testing kits, immunotherapy vaccines, immunohistochemistry antibodies…
Serves NHS and private hospitals, immunology and cellular pathology laboratories, dermatology and allergy clinics, and distributors; also offers at-home antibody testing to consumers.
Financial Health
HealthyHealthy · Growing · 1% CAGR over 4y
Location
Trajectory
3y · 2024–NowFinancial sub-scores
Computed from 3 filingsDevelops and supplies diagnostic DNA testing kits, reagents and analysis tools for clinical laboratories. Products support genetic testing in areas including transplantation monitoring, oncology,…
Serves clinical and genetic diagnostic laboratories, including transplant, oncology, hematology and reproductive health labs, plus specialist distributors worldwide.
Financial Health
StrongStrong · Profitable, Hiring · 41% CAGR over 2y
Location
CAMBRIDGE LIFE SCIENCES LIMITED
Trajectory
5y · 2021–NowFinancial sub-scores
Computed from 5 filingsDevelops, manufactures and supplies in vitro diagnostic assays and test kits for clinical laboratories, including therapeutic drug monitoring, autoimmune disease and gastrointestinal infection tests.…
Serves clinical laboratories, hospitals, endoscopy units and healthcare professionals worldwide, plus OEM partners and distributors seeking in vitro diagnostic products.
Financial Health
DistressedDistressed · -70% CAGR over 4y
Location
Pharmexcel Ltd
Trajectory
5y · 2021–NowFinancial sub-scores
Computed from 5 filingsProvides contract research services for clinical trials, including Phase I–IV study management and oversight. Works with biopharma and medical device companies, universities, and NHS organisations to…
Targets clinical trial sponsors in the NHS, universities, biopharma and medical device sectors, including organisations running Phase I-IV, ATMP, rare disease and device studies.
Financial Health
StrongStrong · Growing, Hiring · 5% CAGR over 4y
Location
MC DIAGNOSTICS LIMITED
Trajectory
5y · 2021–NowFinancial sub-scores
Computed from 5 filingsDevelops and supplies molecular diagnostic assays and instruments for immunogenetics, transplantation and transfusion testing. Provides HLA typing services, multiplex assay development, microarray…
Serves healthcare and laboratory organisations in the UK and Ireland, including transplant and transfusion diagnostics labs, blood banks, immunogenetics, microbiology and human genetics teams.
Financial Health
StableStable · 0% CAGR over 4y
Location
Galvany Pharma Limited
Trajectory
3y · 2023–NowFinancial sub-scores
Computed from 3 filingsDevelops and commercialises niche pharmaceutical medicines across multiple therapeutic areas. Manages a portfolio of prescription drugs, including injectable treatments, and works with manufacturing…
Serves prescribers, community pharmacies, retail pharmacy chains and hospital customers seeking niche medicines, and engages pharmaceutical manufacturers and commercial partners for co-development,…
Financial Health
WeakWeak
Location
Pharmidex Pharmaceutical Services Limited
Trajectory
5y · 2023–NowFinancial sub-scores
Computed from 5 filingsProvides contract research services supporting drug discovery and development, including bioanalysis, ADMET and pharmacokinetics studies, DMPK, toxicology, biomarker analysis, medicinal chemistry, in…
Sells to biopharma, pharmaceutical and medical device companies needing CRO support for drug discovery, preclinical and clinical development. Serves research and development teams in CNS, oncology,…
Financial Health
StrongStrong · -7% CAGR over 2y
Location
Emmes Biopharma UK Limited
Trajectory
3y · 2023–NowFinancial sub-scores
Computed from 3 filingsProvides contract research organisation services for biopharmaceutical and government clients, including clinical trial design and management, biostatistics, clinical data management, regulatory…
Serves government health agencies, public-private research partnerships, and commercial biopharma and medical device companies running clinical trials across therapeutic areas.
Financial Health
WeakWeak · -16% CAGR over 2y
Location
INFEX THERAPEUTICS LIMITED
Trajectory
3y · 2023–NowFinancial sub-scores
Computed from 3 filingsDevelops and licenses anti-infective pharmaceuticals targeting pandemic and drug‑resistant infections. Acquires and advances drug candidates, conducts research and clinical development of…
Serves pharmaceutical partners, clinical trial networks and healthcare providers working in infectious
Financial Health
WeakWeak · 4% CAGR over 2y
Location
ALDERLEY ANALYTICAL LTD
Trajectory
5y · 2021–NowFinancial sub-scores
Computed from 5 filingsProvides contract bioanalytical laboratory services for pharmaceutical and biotechnology drug development, including preclinical and clinical bioanalysis, toxicokinetics, immunogenicity and biomarker…
Serves pharmaceutical, biotechnology and contract research organisations running drug development programmes, from discovery through pre-clinical safety testing to clinical development.
Financial Health
WeakWeak · -64% CAGR over 4y
Location
SYNEXA LIFE SCIENCES LTD
Trajectory
5y · 2020–NowFinancial sub-scores
Computed from 5 filingsProvides contract research laboratory services for pharmaceutical and biotechnology companies, including biomarker identification, bioanalytical testing, and development and validation of assays…
Targets pharmaceutical and biotech sponsors developing therapeutics in oncology, autoimmune disease, vaccines, biosimilars and ADCs, including teams running translational studies and clinical trials.
Financial Health
StableStable · -52% CAGR over 5y
Location
ACM GLOBAL CENTRAL LABORATORY LTD
Trajectory
3y · 2023–NowFinancial sub-scores
Computed from 3 filingsProvides laboratory services for pharmaceutical clinical trials, including bioanalytical testing, biomarker and pharmacokinetic analysis, central laboratory testing, toxicology screening, and sample…
Serves pharmaceutical and biotech companies, clinical trial sponsors and research teams running global drug development programmes, plus healthcare providers needing toxicology and medication…
Financial Health
StrongStrong · Profitable, Growing, Hiring · 10% CAGR over 2y
Location
HILLTOP LEAF HOLDINGS LIMITED
Trajectory
5y · 2021–NowFinancial sub-scores
Computed from 5 filingsCultivates cannabis and operates extraction and processing facilities to manufacture cannabis‑based medicinal products for human use. Produces full‑spectrum medicinal cannabis under regulatory…
Targets B2B healthcare and pharmaceutical partners—clinical distributors, specialist prescribers and medicinal cannabis clinics—serving prescription patients in the UK and Europe.
Financial Health
StrongStrong
Location
THERADEX (EUROPE) LIMITED
Trajectory
4y · 2022–NowFinancial sub-scores
Computed from 4 filingsProvides oncology-focused clinical research organisation (CRO) services for pharmaceutical and biotechnology companies, including clinical trial management, data management, monitoring, and…
Serves B2B oncology sponsors in the pharmaceutical and biotech industry, especially early-stage drug developers, as well as public-sector cancer research organisations such as the U.S. National…
Financial Health
StrongStrong · Profitable, Growing · 0% CAGR over 3y
Location
HILLTOP LEAF LIMITED
Trajectory
5y · 2021–NowFinancial sub-scores
Computed from 5 filingsCultivates and processes medicinal cannabis for use in cannabis‑based products for medicinal use in humans (CBPMs). Operates controlled cultivation, extraction and EU GMP processing facilities to…
Serves B2B healthcare and pharmaceutical buyers, including clinical and distribution partners prescribing or supplying cannabis-based medicines, and targets specialist prescribers and UK and European…
Financial Health
WeakWeak · -59% CAGR over 4y
Location
Develops small‑molecule targeted medicines for fibrotic diseases and cancer. Conducts drug discovery and clinical development of inhibitors targeting pathways such as ROCK, porcupine, KRAS and RAF,…
Targets pharmaceutical and biotech partners seeking clinical-stage small-molecule programmes in fibrotic disease and oncology, alongside investors in biotechnology drug development.
Location
BLUE EARTH THERAPEUTICS LIMITED
Trajectory
3y · 2023–NowFinancial sub-scores
Computed from 3 filingsDevelops targeted radiopharmaceutical and radioligand therapies for the treatment of cancer. Conducts research and development of compounds designed to deliver radiation directly to tumours while…
Targets healthcare professionals, oncology specialists and clinical research partners involved in cancer care and radiopharmaceutical therapy, with patients who have cancer as the ultimate end users.
Financial Health
StrongStrong · Hiring · 41% CAGR over 2y
Location
BIOGRAD LIMITED
Trajectory
5y · 2020–NowFinancial sub-scores
Computed from 5 filingsProvides clinical trial services, biobanking, and human tissue sample collection and storage. Develops biomanufacturing capabilities for advanced cell therapies, including stem cell and CAR‑T…
Serves private and NHS hospitals, UK and international biotech and pharmaceutical companies, academic researchers, and government bodies.
Financial Health
StrongStrong · Growing, Hiring · 29% CAGR over 4y
Location
Cell Projects Limited
Trajectory
5y · 2021–NowFinancial sub-scores
Computed from 5 filingsDevelops and manufactures molecular biology and diagnostics products, including DNA and RNA collection, stabilisation and isolation kits and laboratory consumables for PCR, electroporation and sample…
Serves B2B life sciences researchers, molecular diagnostics developers, IVD manufacturers and forensic laboratories needing DNA/RNA sample products, consumables, contract manufacturing or development…
Financial Health
HealthyHealthy · -4% CAGR over 4y
Location
THE FOUNDRY (CAMBRIDGE) LIMITED
Trajectory
4y · 2022–NowFinancial sub-scores
Computed from 4 filingsProvides outsourced drug discovery and development services for pharmaceutical and biotechnology clients, including in silico molecule design, antibody discovery, medicinal and synthetic chemistry,…
Serves biotechnology and pharmaceutical companies developing small-molecule or biologic drug candidates, including teams needing outsourced discovery, preclinical development and project support…
Financial Health
StableStable · -13% CAGR over 3y
Location
IMMUNODIAGNOSTIC SYSTEMS LIMITED
Trajectory
3y · 2023–NowFinancial sub-scores
Computed from 3 filingsDevelops, manufactures and distributes in‑vitro diagnostic products for clinical and research laboratories, including automated immunoassay systems, ELISA and chemiluminescence assays, instruments…
Serves B2B clinical and research laboratories, diagnostic testing providers, and life science researchers working in endocrinology, autoimmunity, infectious disease, allergy, animal research, and…
Financial Health
HealthyHealthy · -90% CAGR over 2y
Location
ATTOMARKER LIMITED
Trajectory
4y · 2023–NowFinancial sub-scores
Computed from 4 filingsDevelops and supplies multiplex blood testing devices and diagnostic assays that measure multiple biomarkers simultaneously. Uses microfluidic and nanotechnology-based platforms to deliver rapid,…
Serves healthcare professionals, clinics and patients needing rapid biomarker testing, with emphasis on Long COVID, immunology, infection, liver, fertility and allergy-related diagnostics.
Financial Health
StrongStrong · Growing, Hiring · 36% CAGR over 3y
Location
BIOAPP SOLUTIONS LIMITED
Trajectory
5y · 2021–NowFinancial sub-scores
Computed from 5 filingsProvides contract research and analytical laboratory services for pharmaceutical and biotechnology development, including assay development, method development and validation, and analysis supporting…
Serves pharmaceutical, biotech, CRO and clinical research organisations, particularly sponsors running discovery, nonclinical and clinical development programmes needing outsourced analytical support…
Financial Health
StrongStrong · Growing · 0% CAGR over 4y
Location
CAMBRIDGE CLINICAL LABORATORIES LTD
Trajectory
5y · 2021–NowFinancial sub-scores
Computed from 5 filingsProvides clinical laboratory testing services including molecular diagnostics, oncology and virology assays, next‑generation sequencing, pharmacogenetic and patient profiling tests. Processes samples…
Serves NHS organisations, private healthcare providers, clinicians and other healthcare professionals, as well as private customers seeking personalised healthcare testing and diagnostic support.
Financial Health
DistressedDistressed · -5% CAGR over 4y
Location
CHAMPIONS ONCOLOGY UK LIMITED
Trajectory
3y · 2023–NowFinancial sub-scores
Computed from 3 filingsProvides contract research services for oncology drug development, including preclinical studies using patient‑derived tumour models, in vivo and ex vivo testing platforms, and laboratory assays such…
Serves global pharmaceutical and biotech companies, particularly oncology R&D, translational science and clinical development teams working on cancer drug programmes.
Financial Health
DistressedDistressed
Location
PEPCEUTICALS LIMITED
Trajectory
5y · 2021–NowFinancial sub-scores
Computed from 5 filingsSupplies biochemical reagents and raw materials for life science and diagnostic applications, including carbohydrates, nucleosides, peptides, enzymes and antibodies. Provides custom synthesis,…
Serves B2B life sciences and diagnostics markets, including pharmaceutical and biotech companies, IVD manufacturers, research laboratories and manufacturers with GMP/CDMO supply chain needs.
Financial Health
WeakWeak · -72% CAGR over 4y
Location
Charles River U.K. Limited
Trajectory
2y · 2023–NowFinancial sub-scores
Computed from 2 filingsBreeds and supplies laboratory animal models and provides preclinical research services for biomedical and pharmaceutical development, including genetically engineered models, toxicology and safety…
Serves pharmaceutical and biotech companies, academic and government research institutions, and drug development teams across basic research, discovery, preclinical, clinical and manufacturing stages.
Financial Health
StableStable · 1% CAGR over 1y
Location
STANDARD BIOTOOLS UK LIMITED
Trajectory
3y · 2023–NowFinancial sub-scores
Computed from 3 filingsDevelops and supplies genomic and proteomic research technologies, including CyTOF, Hyperion and Biomark systems, along with consumables, reagents and software. Provides laboratory services and tools…
Sells to life sciences research organisations, including translational and clinical researchers, genomics and proteomics labs, and teams working in infectious disease, neuroscience, agrigenomics,…
Financial Health
HealthyHealthy · Hiring · 22% CAGR over 2y
Location
BIOHIT HEALTHCARE LIMITED
Trajectory
5y · 2021–NowFinancial sub-scores
Computed from 5 filingsSupplies diagnostic tests and laboratory assays for the detection and monitoring of gastrointestinal and digestive diseases. Offers ELISA kits, rapid tests, home testing kits, and therapeutic drug…
Serves NHS trusts, clinical laboratories, endoscopy units, GP/practice clinics, and academic or clinical researchers, with some products aimed at patients managing gastrointestinal conditions.
Financial Health
StrongStrong · Growing, Hiring · 4% CAGR over 4y
Location
HART BIOLOGICALS LIMITED
Trajectory
5y · 2021–NowFinancial sub-scores
Computed from 5 filingsManufactures diagnostic reagents and testing products for haemostasis and platelet function analysis. Produces INR monitoring reagents and instruments, platelet aggregation reagents, fibrinogen…
Serves clinical laboratories, INR clinics and healthcare providers, plus diagnostics manufacturers/OEM partners and EQA/PT scheme operators needing haemostasis, platelet function and coagulation…
Financial Health
StableStable · 2% CAGR over 4y
Location
EDINBURGH GENETICS LIMITED
Trajectory
5y · 2021–NowFinancial sub-scores
Computed from 5 filingsProvides next-generation sequencing products and genomic laboratory services, including library preparation kits, whole genome and exome sequencing, RNA‑seq, metagenomics and bioinformatics. Also…
Serves life science researchers, clinical diagnostic laboratories, clinical trial teams and product developers in healthcare, biotech, agriculture and conservation.
Financial Health
DistressedDistressed · -29% CAGR over 4y
Location
RESEARCH ORGANISATION (KC) LTD
Trajectory
5y · 2021–NowFinancial sub-scores
Computed from 5 filingsProvides clinical research services including design, management and monitoring of multi-centre clinical trials. Offers project management, feasibility and trial design, clinical informatics, quality…
Serves pharmaceutical, academic and biotechnology organisations running pan-European clinical trials, especially late-phase and post-marketing studies in HIV, hepatitis, Covid-19 and infectious…
Financial Health
HealthyHealthy · Profitable, Hiring · 9% CAGR over 4y
Location
MERIDIAN BIOSCIENCE INTERNATIONAL LIMITED
Trajectory
4y · 2020–NowFinancial sub-scores
Computed from 4 filingsDevelops and manufactures molecular and immunological reagents, diagnostic assays, and testing platforms for clinical diagnostics and life science research. Products include PCR master mixes,…
Sells primarily to healthcare laboratories, diagnostic providers, life science researchers and commercial assay developers needing molecular and immunological reagents, diagnostic tests and…
Financial Health
StableStable · -12% CAGR over 4y
Location
Trajectory
2y · 2023–NowFinancial sub-scores
Computed from 2 filingsDevelops and clinically tests biopharmaceutical drugs and precision cancer vaccines for treatment‑resistant cancers. Pipeline includes small‑molecule inhibitors such as zabadinostat and PRMT5…
Targets patients with advanced-stage, treatment-resistant cancers, especially lymphoma, colorectal cancer and liver cancer, where standard chemotherapy or immunotherapy offers limited benefit.
Financial Health
WeakWeak
Location
WREN LABORATORIES LIMITED
Trajectory
5y · 2019–NowFinancial sub-scores
Computed from 5 filingsDevelops and performs mRNA‑based liquid biopsy diagnostic tests for cancer detection and monitoring. Provides multi‑gene expression assays including NETest and PROSTest for neuroendocrine and…
Serves cancer care providers, oncologists and patients, plus biopharma and research teams involved in precision oncology, drug development and companion diagnostics.
Financial Health
StableStable · -51% CAGR over 6y
Location
Unlock all 2,474 leads
Showing 50 of 2,474 — +2,424 more with verified decision-maker contacts, live data, and CRM sync.
How UK biotech companies work and how to sell to them
What they do
Revenue usually comes from a mix of research-service contracts, platform-access fees, licensing, staged collaboration payments, regulated process work and, for mature operators, product sales after approval. Many biotech firms are selling evidence rather than a finished package: assay performance, biological insight, clinical progress, process reliability or rights to an asset. Pricing is often milestone-based or scoped around work packages, with payment terms tied to validation, delivery, exclusivity or transfer of rights. Where firms provide services, engagement can look closer to specialist professional services or contract development. Where they own assets, the commercial model depends on partnering, licensing or acquisition appetite as much as direct end-customer demand.
Who they sell to
Most customers are biopharmaceutical groups, health R&D organisations, clinical-trial sponsors, manufacturing partners, diagnostics-adjacent operators and, in some cases, public-sector health bodies. Buying committees usually include chief scientific officers, heads of R&D, clinical operations, regulatory affairs, quality, procurement and finance; corporate development often joins when rights, licensing or acquisition options are involved. Sales cycles tend to be longer than ordinary business software procurement because buyers need scientific review, safety evidence, quality documentation and legal diligence. Direct business development is common for platforms and assets, while services, manufacturing and trial-related work may pass through approved-supplier processes, formal tenders or partner-led procurement routes.
What they buy
Biotech firms tend to spend on systems and services that help them produce, protect and explain evidence. Common categories include laboratory information management, electronic lab notebooks, clinical-trial operations tools, regulatory-document management, quality management, pharmacovigilance workflows, data storage, analytics, cybersecurity and finance systems that can handle grant, collaboration or milestone income. Outside software, they often buy intellectual-property advice, regulatory consulting, clinical operations support, specialist recruitment, accounting, investor communications, lab facilities, equipment servicing and outsourced development or manufacturing capacity. Sellers should expect validation questions, security reviews and evidence of how a product fits regulated workflows, rather than a simple productivity-led purchase conversation.
Why and how to sell to them
Commercial intent often appears when a biotech firm moves from discovery into clinical preparation, wins a collaboration, expands regulated manufacturing activity, hires senior clinical or quality leadership, or prepares for partner diligence. Pain points tend to cluster around audit readiness, fragmented research records, slow evidence assembly, talent shortages, cash discipline and the need to satisfy external reviewers without distracting scientific teams. Outbound angles work better when framed around reducing validation friction, improving traceability, shortening handover between R&D and regulated operations, or making partner and investor diligence less labour-intensive. Generic growth claims are unlikely to land; buyers usually want proof that a supplier understands scientific, quality and approval constraints.
How this list is built
Data sources
This list is built from UK Companies House filings, XBRL accounts data, and semantic analysis of each company's public website. Revenue and headcount figures come from the most recent filed accounts; where the company has not filed, values are estimated using a model trained on filed history and peer benchmarks and are labelled as estimates.
Classification
Rather than relying solely on SIC codes, Firmbase classifies each company semantically: the company's website is crawled, an AI model reads what the company actually sells, and the company is placed into the relevant industry and subsectors. SIC codes are used as one signal but not the only one. This means a company that registered under a generic SIC code but pivoted into (for example) fintech is correctly identified as fintech, not as its original SIC category.
Freshness
The underlying company data is refreshed from Companies House continuously; filings appear in the list within days of submission. The curated list ordering is regenerated when the underlying data moves meaningfully (company count changes by more than 5%, a new company enters the top-ranked segment, or the filed-revenue numbers for the top firms change). You can see the last-updated timestamp near the top of the page.
Related directories
Frequently asked questions
How many biotech companies are there in the UK?↓
What counts as a biotech company in this list?↓
Which are the largest biotech companies in the UK?↓
What do biotech companies in the UK actually do?↓
How does UK biotech compare internationally?↓
How is this list built and how fresh is the data?↓
How big are the typical biotech companies in the UK?↓
Are these mostly new or established biotech companies?↓
What SIC codes does this use?↓
What buying signals should I look for?↓
Push these 2,474 companies into your pipeline.
Find the right decision-makers, see verified company data, and export your list in seconds.